• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?治疗骨髓增生异常综合征的新药：它们正在改变输血支持的作用吗？
Blood Transfus. 2008 Oct;6(4):191-8. doi: 10.2450/2008.0009-08.
2
A new case of isolated del(12)(q15q22) in myelodysplastic syndrome.12号染色体长臂15区至22区孤立性缺失的骨髓增生异常综合征新病例。
Cancer Genet Cytogenet. 2001 Oct 1;130(1):89-91. doi: 10.1016/s0165-4608(01)00472-1.
3
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.停用来那度胺的del(5q)骨髓增生异常综合征患者的长期输血独立性
Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30.
4
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.定义早期骨髓增生异常综合征伴5q缺失患者的疾病进展模式存在困难，因此需要新的预后标志物。
Leuk Res. 2014 Mar;38(3):287-8. doi: 10.1016/j.leukres.2013.12.013. Epub 2013 Dec 26.
5
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.低甲基化药物在骨髓增生异常综合征中的应用：改变不可避免的结局——阿扎胞苷作为维持治疗的价值、对输血的影响以及与其他药物联合应用。
Leuk Res. 2009 Dec;33 Suppl 2:S18-21. doi: 10.1016/S0145-2126(09)70229-2.
6
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.来那度胺治疗伴有 5q 染色体缺失的低危或中危-1 级细胞遗传学风险的输血依赖型骨髓增生异常综合征患者的健康相关生活质量结局：一项随机临床试验的结果。
Leuk Res. 2013 Mar;37(3):259-65. doi: 10.1016/j.leukres.2012.11.017. Epub 2012 Dec 27.
7
[Current treatment options for myelodysplastic syndromes].[骨髓增生异常综合征的当前治疗选择]
Dtsch Med Wochenschr. 2010 Sep;135(38):1863-9. doi: 10.1055/s-0030-1263328. Epub 2010 Sep 14.
8
[9th Antonio Raichs memorial lecture. Myelodysplastic syndromes].
Sangre (Barc). 1997 Feb;42(1):63-71.
9
Progress in the treatment of myelodysplastic syndromes.骨髓增生异常综合征的治疗进展
Blood Transfus. 2008 Oct;6(4):180-1. doi: 10.2450/2008.0044-08.
10
[Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes].来那度胺治疗依赖输血的骨髓增生异常综合征
Ugeskr Laeger. 2010 Feb 8;172(6):452-5.

引用本文的文献

1
Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.放疗和化疗诱发的骨髓增生异常综合征：一项基于全国人群的巢式病例对照研究。
Medicine (Baltimore). 2015 May;94(17):e737. doi: 10.1097/MD.0000000000000737.
2
Lenalidomide-induced acute liver failure.来那度胺诱发的急性肝衰竭。
Blood Transfus. 2009 Oct;7(4):335-6; author reply 337. doi: 10.2450/2009.0086-09.
3
Progress in the treatment of myelodysplastic syndromes.骨髓增生异常综合征的治疗进展
Blood Transfus. 2008 Oct;6(4):180-1. doi: 10.2450/2008.0044-08.

本文引用的文献

1
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.影响接受免疫抑制治疗的骨髓增生异常综合征患者反应和生存的因素。
J Clin Oncol. 2008 May 20;26(15):2505-11. doi: 10.1200/JCO.2007.11.9214. Epub 2008 Apr 14.
2
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.输血依赖和继发性铁过载对骨髓增生异常综合征患者生存的影响。
Leuk Res. 2007 Dec;31 Suppl 3:S2-6. doi: 10.1016/S0145-2126(07)70459-9.
3
Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis.促红细胞生成蛋白在骨髓增生异常综合征中的疗效和安全性：一项系统评价和荟萃分析。
Oncologist. 2007 Oct;12(10):1264-73. doi: 10.1634/theoncologist.12-10-1264.
4
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.促红细胞生成素和粒细胞集落刺激因子治疗骨髓增生异常综合征的反应和生存预测因素：GFM研究经验
Blood. 2008 Jan 15;111(2):574-82. doi: 10.1182/blood-2007-06-096370. Epub 2007 Oct 16.
5
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.来那度胺用于除5q缺失外其他核型的输血依赖型、低危和中危-1型骨髓增生异常综合征的2期研究。
Blood. 2008 Jan 1;111(1):86-93. doi: 10.1182/blood-2007-01-068833. Epub 2007 Sep 24.
6
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.骨髓增生异常综合征（MDS）患者低国际前列腺症状评分（IPSS）及骨髓细胞减少预示着其对抗胸腺细胞球蛋白的血液学反应。
Leukemia. 2007 Jul;21(7):1436-41. doi: 10.1038/sj.leu.2404747. Epub 2007 May 17.
7
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
8
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.5-氮杂-2'-脱氧胞苷与丙戊酸联合用于白血病患者的1/2期研究。
Blood. 2006 Nov 15;108(10):3271-9. doi: 10.1182/blood-2006-03-009142. Epub 2006 Aug 1.
9
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.联合DNA甲基转移酶和组蛋白脱乙酰酶抑制用于治疗髓系肿瘤
Cancer Res. 2006 Jun 15;66(12):6361-9. doi: 10.1158/0008-5472.CAN-06-0080.
10
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.高剂量α-达贝泊汀治疗低危骨髓增生异常综合征贫血的II期研究结果
Br J Haematol. 2006 Jun;133(5):513-9. doi: 10.1111/j.1365-2141.2006.06070.x.

New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

作者信息

Grossi Alberto, Liumbruno Giancarlo Maria

机构信息

Associazione Italiana per la Lotta contro le Leucemie, Linfomi e Mieloma (AIL), Prato, Italy.

出版信息

Blood Transfus. 2008 Oct;6(4):191-8. doi: 10.2450/2008.0009-08.

DOI:10.2450/2008.0009-08
PMID:19112734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2626911/
Abstract
摘要